Caroline Kimberly Pocher (on behalf of Tessa Romero)'s questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q3 2024
Question
Caroline Kimberly Pocher, on behalf of Tessa Romero, asked for the timeline to learn more about the clinical profile of the lead Nav1.7 candidate and inquired about the potential design of a proof-of-concept study.
Answer
CEO Ian Mortimer explained that specific details like receptor occupancy are being kept confidential for competitive reasons, but affirmed they have a molecule with the right profile to test the hypothesis in humans. He outlined the clinical plan, which includes a first-in-human SAD/MAD study followed by a proof-of-concept study, likely in a bunionectomy model.